Fraud, abuse and overpayment increases annual claims costs by up to 10% annually, but if addressed with a comprehensive fraud control program, could be money returned to the bottom line.
Fraud, Abuse And overpayment increases annual claims costs by up to 10% annually, but if addressed with a comprehensive fraud control program, could be money returned to the bottom line.
"Provider and member fraud can drive up the price of healthcare and diminish the quality of care," says David Deaton, a partner in O'Melveny & Myers LLP's Los Angeles office and a member of the Health Care and Life Sciences Practice. "An effective fraud control program can lower premiums, increase quality for members, make healthcare coverage more accessible and protect the financial viability of a health plan."
Experts say that fighting fraud and abusive billing practices is a continually evolving process-not a single event. "In order to fight fraud effectively, you need to understand that fraud is a moving target, constantly changing and evolving. Once you've uncovered one fraudulent scheme, the most sophisticated perpetrators have moved on to a new scheme," explains Brian Smith, HCI's senior vice president of sales. "ASPs [application service providers] and SaaS [software as a service] solutions are allowing health plans to use advanced analytics, similar to what the banking industry has used for decades, to apply rules-based logic in order to prevent overpayments and detect aberrant and fraudulent provider billing trends."
A comprehensive fraud, abuse and overpayment program can typically save MCOs 1% to 5% annually. The range depends on the cost controls currently in place and the action level of the MCO. "Some MCOs are more aggressive when it comes to recovering or preventing loss attributed to fraud and abuse, and some opt to monitor and educate providers," Johnson says.
The most common fraud schemes include:
-Tracey Walker
Commentary is independent of source data
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Lifts Safety Restrictions on CAR T Therapies After Reviewing Real-World Data
July 2nd 2025FDA officials have determined that information regarding the risks for six CAR T-cell therapies can be communicated through product labeling, which includes a boxed warning for the risks of cytokine release syndrome and neurological toxicities.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen